CareFusion, Terumo Sign Distribution Agreement For IV Catheters

       CareFusion, Terumo Sign Distribution Agreement For IV Catheters

Eight-Year Exclusive Agreement for CareFusion to Market SurFlash® Catheters in
U.S. Acute Care Segment

PR Newswire

SAN DIEGO, Jan. 29, 2014

SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- CareFusion (NYSE:CFN), a leading
global medical technology company, and Terumo Corporation, the largest medical
technology company in Japan, today announced an exclusive, eight-year
agreement for CareFusion to co-brand, market and distribute Terumo's
SurFlash^® line of safety peripheral IV catheters for the acute care segment
across the United States.

The agreement includes both SurFlash and SurFlash Plus Safety IV Catheters,
which are proven to improve the success of catheter placement on the first
attempt by an average of 20 percent. The higher success rate for first
placement can potentially enhance the patient experience, reduce wasted
catheters and save clinician time, all of which reduce costs for the hospital.

"This agreement broadens our vascular access portfolio and adds a critical
link to enable CareFusion to provide an expanded range of products," said
Vivek Jain, president of Procedural Solutions for CareFusion. "From skin
preparation to needle-free connectors and IV sets, the SurFlash brand builds
on our established leadership of clinically differentiated products for
vascular access procedures. We are proud to collaborate with a global medical
technology leader like Terumo."

Terumo's agreement with CareFusion will focus solely on the U.S. acute care
hospital market.

"CareFusion's world-class clinical and commercial presence in acute care
infusion will accelerate the U.S. market impact of these safety products
faster than Terumo might otherwise achieve,"said Hideo Arase, president and
CEO of Terumo Medical Corporation and Terumo Americas Holding, Inc. "The
synergies are clear."

SurFlash and SurFlash Plus Safety IV Catheters have a passive safety
technology that completely encapsulates the needle reducing the risk of needle
stick injuries and exposure to blood borne pathogens. The automatic engagement
of this safety feature requires no intentional effort from the clinician,
allowing for minimal technique change and faster adoption. These products are
also the only catheters with the double-flash SurFlash feature that gives
visual confirmation of when both the needle and catheter gain entry into a
vessel, minimizing the risk for failed attempts.

The SurFlash Plus Safety IV Catheter also incorporates a proprietary blood
control safety valve designed to minimize the risk of blood exposure between
the removal of the needle and the attachment of the IV set. This helps create
a cleaner access site and IV hub area to reduce the risk of physical and
visual exposure to blood.

CareFusion will begin to market and distribute these products this month.
Financial terms of the agreement were not disclosed.

About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the health care
industry with products and services that help hospitals measurably improve the
safety and quality of care. The company develops industry-leading technologies
including Alaris^® infusion pumps and IV sets, MaxPlus^® and MaxZero^™ IV
connectors and sets, Pyxis^® automated dispensing and patient identification
systems, AVEA^®, LTV^® series and AirLife^® ventilation and respiratory
products, ChloraPrep^® products, MedMined^® services for data mining
surveillance, V. Mueller^® surgical instruments, and an extensive line of
products that support interventional medicine. CareFusion employs
approximately 15,000 people across its global operations. More information may
be found at www.carefusion.com.

About Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation
(TMC) develops, manufactures, and markets high-quality medical devices used in
a broad range of applications in numerous healthcare markets. TMC manufactures
a broad portfolio of needles and syringes, entry-site management products, and
a line of sterile connection devices used in hospitals and blood banks
worldwide.

About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device
manufacturers with $4.95 billion in sales and operations in more than 160
nations. Founded in 1921, the company develops, manufactures, and distributes
world-class medical devices including products for use in cardiothoracic
surgery, interventional procedures, and transfusion medicine; the company also
manufactures a broad array of syringe and hypodermic needle products for
hospital and physician office use. Terumo contributes to society by providing
valued products and services to the healthcare market and by responding to the
needs of healthcare providers and the people they serve. Terumo Corporation's
shares are listed on the first section of the Tokyo Stock Exchange (No. 4543,
Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the
Nikkei 225, Japan's leading stock index.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

SOURCE CareFusion Corporation

Website: http://www.carefusion.com
Contact: Media: Troy Kirkpatrick, (858) 617-2361,
troy.kirkpatrick@carefusion.com; Investors: Jim Mazzola, (858) 617-1203,
jim.mazzola@carefusion.com
 
Press spacebar to pause and continue. Press esc to stop.